Skip to content
ContentLora

    Tip: press / anywhere to search.

    FDA novel drug approvals by year, 2021 to 2026

    The FDA's drug center approved 50 novel drugs in 2021[1] and 37 in 2022.[2] The count rose to 55 in 2023[3] and was 50 in 2024[4] and 46 in 2025.[5] The 2026 list had 48 entries by 14 November.[6]

    Health and medicineStatistics and evidenceUpdated · Units: novel drugs approved

    Chart

    Bar chart: FDA novel drug approvals by year, 2021 to 2026 (novel drugs approved)Novel drugs approved by CDER: 2021 50; 2022 37; 2023 55; 2024 50; 2025 46; 2026 (to 14 Nov) 48.0204060novel drugs approved202120222023202420252026 (to 14 Nov)50Novel drugs approved by CDER, 2021: 50 novel drugs approved37Novel drugs approved by CDER, 2022: 37 novel drugs approved55Novel drugs approved by CDER, 2023: 55 novel drugs approved50Novel drugs approved by CDER, 2024: 50 novel drugs approved46Novel drugs approved by CDER, 2025: 46 novel drugs approved48Novel drugs approved by CDER, 2026 (to 14 Nov): 48 novel drugs approved

    Notes. The FDA counts as novel any new drug never before approved or marketed in the US, and these lists cover approvals by its Center for Drug Evaluation and Research (CDER).[7] They include new molecular entities approved under New Drug Applications and new therapeutic biological products approved under Biologics License Applications.[8] The 2026 bar is a partial year: the latest entry on the list as of 14 November was Sunharbo (asundexian), approved on 9 November.[6]

    Data table

    FDA novel drug approvals by year, 2021 to 2026, in novel drugs approved, with the claim behind each value
    PeriodValue (novel drugs approved)SourceClaim as of
    50[1]2026-11-14
    37[2]2026-11-14
    55[3]2026-11-14
    50[4]2026-11-14
    46[5]2026-11-14
    48[6]2026-11-14

    Download CSV · Timeline of developing stories

    Sources

    · 8 claims from 2 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      The FDA says CDER approved 50 novel drugs in 2021. confirmedas of 2026-11-14

    2. [2]

      The FDA says CDER approved 37 novel drugs in 2022. confirmedas of 2026-11-14

    3. [3]

      The FDA says CDER approved 55 novel drugs in 2023. confirmedas of 2026-11-14

    4. [4]

      The FDA says CDER approved 50 novel drugs in 2024. confirmedas of 2026-11-14

    5. [5]

      The FDA says CDER approved 46 novel drugs in 2025; the last on its list, Nereus (tradipitant), was approved on 30 December 2025. confirmedas of 2026-11-14

    6. [6]

      The FDA's list of 2026 novel drug approvals had 48 entries as of 14 November 2026, from Zycubo (copper histidinate) on 12 January to Sunharbo (asundexian) on 9 November. confirmedas of 2026-11-14

      • Novel Drug Approvals for 2026 · US Food and Drug Administration · Primary source · Novel drug approvals 2026, top row of the table (rows are numbered 1-48) (retrieved 2026-11-14)
      • Novel Drug Approvals for 2026 · US Food and Drug Administration · Primary source · Novel drug approvals 2026, last row of the table (retrieved 2026-11-14)
    7. [7]

      The FDA defines novel drugs as new drugs never before approved or marketed in the United States; its annual lists cover novel drugs approved by CDER, its Center for Drug Evaluation and Research. confirmedas of 2026-11-14

    8. [8]

      CDER's novel approvals include both new molecular entities approved under New Drug Applications and new therapeutic biological products approved under Biologics License Applications. confirmedas of 2026-11-14